ERBB2 and breast carcinoma: Kallergi et al. [17] examined the expression of cytokeratin/C-X-C chemokine receptor type 4/transcription factor jun-B (CK/CXCR4/JUNB) in DTCs isolated from the bone marrow (BM) of 39 HR-positive, HER2-negative breast cancer patients and compared them to that in breast cancer cell lines.